Trial Profile
Immunogenicity and efficacy of the vaccine against Hepatitis B virus in immunosuppressed patients antiHBc positive with low titers of anti-HBs. Assessment of clinical usefulness in preventing reactivation of HBV infection.
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 13 Sep 2019
Price :
$35
*
At a glance
- Drugs Hepatitis B vaccine recombinant (HBvaxPro) (Primary)
- Indications Hepatitis B
- Focus Pharmacodynamics; Therapeutic Use
- Acronyms HEPBARE
- 27 Aug 2015 New trial record